Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adamis Pharmaceuticals Corporation

http://www.adamispharmaceuticals.com/

Latest From Adamis Pharmaceuticals Corporation

Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology

Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.

Finance Watch Restructuring

Chinese Biotechs Ascend Deal-Making By Partnering Up Claudin 18.2 Agents

The recent partnerships on Claudin 18.2-targeting agents between Chinese biotechs and big pharma have brought China innovation to a new phase that Chinese firms can be proud of, an executive from Keymed Biosciences, one of the Chinese biotechs involved in such deals, tells Scrip in an interview.

China Deals

Competition Grows In Claudin18.2 As AstraZeneca Seals Antibody Conjugate Deal

Already a major player in the field thanks to Enhertu, AstraZeneca is doubling down in gastric cancer with the new antibody-drug conjugate deal with China’s KYM Biosciences.

Commercial Deals

Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate

Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids. 

Prescription To OTC Switch FDA
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Biosyn Inc.
    • Cellegy Holdings Inc
    • US Compounding, Inc.
UsernamePublicRestriction

Register